YOU ARE HERE:
3 x 5: South Africa, India, Nigeria `have to start moving` says WHO
There is a strong likelihood that the World Health Organization's 3 x 5 target to get three million people onto antiretroviral treatment by the end of 2005 could fail unless governments in South Africa, India and Nigeria show greater commitment to reaching treatment targets, according to Dr Jim Kim of the World Health Organization. He was speaking on the opening day of the Twelfth Annual Retroviruses conference, held this year in Boston, USA.
Only two countries - Botswana and Brazil - have met their targets for scale up, he said. Mozambique, Malawi, Burundi and Uganda have made good progress, and in each case the 3 x 5 target has been an important spur to expand treatment. On the other hand, South Africa, India and Nigeria "have to start moving". Countries such as Zambia, Swaziland and Lesotho will meet their targets, which could be "quite embarrassing for South Africa if they only reach 10% of their target by the end of 2005."
Dr Kim identified four factors considered critical for scale up: political will, access to affordable drugs, accelerated prevention through the scale up of treatment and a public health approach to treatment scale-up.
Securing the supply of generic drugs through the prequalification programme must continue and the programme must be defended, said Dr Kim. However, procurement and supply chain management is the major bottleneck in the view of the Global Fund to Fight AIDS.
Dr Kim appealed to the audience at the Twelfth Annual Retroviruses conference to support the public health approach to antiretroviral therapy. The public health approach is designed to work in settings where doctors are in short supply and the health care infrastructure is poor, and provides standardised regimens for use in large numbers of patients where hi-tech monitoring is lacking.
The DART trial, which uses a public health approach to treatment, shows significantly better outcomes than the historical Entebbe cohort; after 1.25 years on treatment, less than 5% of the DART participants had died, compared to around 50% of the untreated Entebbe cohort.
Dr Kim appealed for three forms of help from the audience and the wider international research community.
Only two countries - Botswana and Brazil - have met their targets for scale up, he said. Mozambique, Malawi, Burundi and Uganda have made good progress, and in each case the 3 x 5 target has been an important spur to expand treatment. On the other hand, South Africa, India and Nigeria "have to start moving". Countries such as Zambia, Swaziland and Lesotho will meet their targets, which could be "quite embarrassing for South Africa if they only reach 10% of their target by the end of 2005."
Dr Kim identified four factors considered critical for scale up: political will, access to affordable drugs, accelerated prevention through the scale up of treatment and a public health approach to treatment scale-up.
Securing the supply of generic drugs through the prequalification programme must continue and the programme must be defended, said Dr Kim. However, procurement and supply chain management is the major bottleneck in the view of the Global Fund to Fight AIDS.
Dr Kim appealed to the audience at the Twelfth Annual Retroviruses conference to support the public health approach to antiretroviral therapy. The public health approach is designed to work in settings where doctors are in short supply and the health care infrastructure is poor, and provides standardised regimens for use in large numbers of patients where hi-tech monitoring is lacking.
The DART trial, which uses a public health approach to treatment, shows significantly better outcomes than the historical Entebbe cohort; after 1.25 years on treatment, less than 5% of the DART participants had died, compared to around 50% of the untreated Entebbe cohort.
Dr Kim appealed for three forms of help from the audience and the wider international research community.
- "Support 3 x 5 - don't get caught up in theorising about whether we will make it or not. It's a focused effort to make the people who can take action take action. Please stop speculating and simply do what you can to make it happen."
- "Please support the public health approach - we know there will be opposition to the public health approach here, but we have no choice but to go forward and do the best we can now."
- "We are screaming for the research that you do to go on being funded, but there is almost no money for the kind of operational research that will help us do what we do better. Tell Tony Fauci that you care about research that may not lead to increased tenure in universities, but will lead to increased tenure of mothers and fathers, of families."
aidsmap resources
Africa news
- People with HIV providing high quality treatment support in community
- Nurse prescribing of ARVs: evidence of success in Rwanda and Lesotho
- Cost-effective ways to reduce loss to follow-up in ART programmes identified
Asia and Pacific news
- Screening tool for HIV in children not being used effectively by health care workers
- Water treatment does not reduce diarrhoea in infants born to Kenyan mothers with HIV
- Pain widespread and rarely relieved in Indian patients with HIV
Conference news
- New hepatitis C protease inhibitors achieve 80% ‘cure’ rate in patients with genotype 1 infection
- Adenovirus link to HIV acquisition diminishing over time in STEP vaccine study
- How much does viral load need to fall to halve HIV transmission risk?
Eastern Europe and Russia news
- Russia urged to expand prevention for injecting drug users
- World Bank: Financial crisis threatens HIV treatment for 1.7 million
- HIV diagnoses in European MSM have almost doubled since 2000, UK tops the list
Latin America news
- Non-AIDS-related deaths becoming more common in Rio de Janeiro HIV patients
- Taking HIV treatment before conception increases risk of having a premature or low weight baby, Brazilian study shows
- CD4 cell count increases sustained up to five years in developing-world treatment programmes
Treatment access news
feedback
Give us your views on our work
